awmsg logo



alemtuzumab (MabCampath®)


Reference No. 14

Publication date:
21/01/2009


Appraisal information

alemtuzumab (MabCampath®) 10 mg/ml concentrate for solution for infusion
alemtuzumab (MabCampath®) 30 mg/ml concentrate for solution for infusion


Company: Bayer Healthcare Pharmaceuticals
BNF category: Malignant disease and immunosupression
NMG meeting date: 12/11/2008
AWMSG meeting date: 10/12/2008
   
   
Submission Type: Full Submission
Status: Marketing authorisation withdrawn
Advice No: 2208
Ministerial ratification: 19/01/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

LICENCE WITHDRAWN. Please refer to the European Medicines Agency website for further information. Alemtuzumab (MabCampath®) is recommended for restricted use within NHS Wales for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate. Alemtuzumab (MabCampath®) should be restricted for use in patients with previously untreated B-CLL with the cytogenetic abnormality 17p-deletion. Alemtuzumab (MabCampath®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download